These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. Byron PR; Hindle M; Lange CF; Longest PW; McRobbie D; Oldham MJ; Olsson B; Thiel CG; Wachtel H; Finlay WH J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S59-69. PubMed ID: 21133801 [TBL] [Abstract][Full Text] [Related]
44. Delivery of antibiotics to the respiratory tract: an update. Traini D; Young PM Expert Opin Drug Deliv; 2009 Sep; 6(9):897-905. PubMed ID: 19637984 [TBL] [Abstract][Full Text] [Related]
45. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Onoue S; Misaka S; Kawabata Y; Yamada S Expert Opin Drug Deliv; 2009 Aug; 6(8):793-811. PubMed ID: 19558334 [TBL] [Abstract][Full Text] [Related]
46. Formulation and clinical perspectives of inhalation-based nanocarrier delivery: a new archetype in lung cancer treatment. Bardoliwala D; Javia A; Ghosh S; Misra A; Sawant K Ther Deliv; 2021 May; 12(5):397-418. PubMed ID: 33902294 [TBL] [Abstract][Full Text] [Related]
47. Treating systemic diseases via the lung. Sanjar S; Matthews J J Aerosol Med; 2001; 14 Suppl 1():S51-8. PubMed ID: 11424894 [TBL] [Abstract][Full Text] [Related]
48. Do healthcare professionals think that dry powder inhalers can be used interchangeably? Price D Int J Clin Pract Suppl; 2005 Dec; (149):26-9. PubMed ID: 16280000 [TBL] [Abstract][Full Text] [Related]
49. Pharmaceutical approaches to colon targeted drug delivery systems. Chourasia MK; Jain SK J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729 [TBL] [Abstract][Full Text] [Related]
50. Novel dry powder inhalation system based on dispersion of lyophilisates. Claus S; Schoenbrodt T; Weiler C; Friess W Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061 [TBL] [Abstract][Full Text] [Related]
54. Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. Hickey AJ; Garcia-Contreras L Crit Rev Ther Drug Carrier Syst; 2001; 18(4):387-431. PubMed ID: 11605897 [TBL] [Abstract][Full Text] [Related]
55. The preparation and application of pulmonary surfactant nanoparticles as absorption enhancers in insulin dry powder delivery. Zhang Y; Zhu J; Tang Y; Chen X; Yang Y Drug Dev Ind Pharm; 2009 Sep; 35(9):1059-65. PubMed ID: 19640250 [TBL] [Abstract][Full Text] [Related]
56. Highly reproducible powder aerosolisation for lung delivery using powder-specific electromechanical vibration. Crowder TM Expert Opin Drug Deliv; 2005 May; 2(3):579-85. PubMed ID: 16296776 [TBL] [Abstract][Full Text] [Related]
57. The influence of pulmonary surfactant on nanoparticulate drug delivery systems. Schleh C; Rothen-Rutishauser B; Kreyling WG Eur J Pharm Biopharm; 2011 Apr; 77(3):350-2. PubMed ID: 21195761 [TBL] [Abstract][Full Text] [Related]
58. Strategies to improve oral drug bioavailability. Gomez-Orellana I Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764 [TBL] [Abstract][Full Text] [Related]
59. Particles and powders: tools of innovation for non-invasive drug administration. Buttini F; Colombo P; Rossi A; Sonvico F; Colombo G J Control Release; 2012 Jul; 161(2):693-702. PubMed ID: 22414325 [TBL] [Abstract][Full Text] [Related]
60. Challenges in inhaled product development and opportunities for open innovation. Forbes B; Asgharian B; Dailey LA; Ferguson D; Gerde P; Gumbleton M; Gustavsson L; Hardy C; Hassall D; Jones R; Lock R; Maas J; McGovern T; Pitcairn GR; Somers G; Wolff RK Adv Drug Deliv Rev; 2011; 63(1-2):69-87. PubMed ID: 21144875 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]